Skip to content

Gout: risk factors and treatment in primary care

Gout: risk factors and treatment in primary care - GRIP study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON47414
Enrollment
681
Registered
2016-11-03
Start date
2017-02-27
Completion date
Unknown
Last updated
2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout Gouty arthritis

Interventions

None listed

Sponsors

Huisartsgeneeskunde
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age: older than 18 years. - Contacted their GP with a gout attack in the year 2013, 2014 or 2015

Exclusion criteria

Exclusion criteria: - Patients with a limited life expectancy. - Patients that are not able (independently or with help) to fill in the Dutch questionnaires.

Design outcomes

Primary

MeasureTime frame
The main study endpoints are the frequency of gout attacks, the presence of tophi and the use of Allopurinol. The presence of gout will be validated according to the ACR-EULAR 2015 criteria for gout and the gout calculator. The frequency and characteristics of gout attacks will be measured using the modified Gout Assessment Questionnaire 2.0. The presence and burden of tophi will be measured using the validated Tophus Impact Questionnaire (TIQ-20). The use of allopurinol will be ascertained using the Brief Medication Questionnaire.

Secondary

MeasureTime frame
1. Demographics measured at baseline using questions derived from the Medical Consumption Questionnaire. 2. Tests include the following laboratory examinations: estimated glomerular filtration rate (eGFR), uric acid level, total cholesterol, low- and high-density-lipoproteïne cholesterol and glucose (fasting). Therefore, at baseline a single venapunction will take place at baseline. Blood pressure will be measured once at baseline. 3. Clinical factors: Comorbidity will be assessed at baseline, 1 year and 2 years FU using the Self-Administered Comorbidity Questionnaire. For calculating BMI, at baseline the patients length and weight will be asked. Physical and mental health will be determined at baseline, 1 year and 2 years using the SF-36 physical and mental component summary [18] and quality of life via the EQ-5D. 4. Medication: The use and adherence to allopurinol and other gout-medication will be evaluated every 3 months. The adherence to prescribed medication and over the counter medication will be measured at baseline, 1 year and 2 years follow-up using a derived version of the Brief Medication Questionnaire. 5. Diet and lifestyle: Dietary intake (consumption of fructose-rich and carbonated beverages, alcohol, purine rich food, lactose and dairy products) will be measured using the Dutch validated Food Frequency Questionnaire, at baseline, 1 and 2 years follow-up. Physical activity will be measured at baseline and hereafter every 6 months with the International physical activity questionnaire. Smoking status will be asked at baseline, 1 year and 2 years follow-up.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)